Ph.D. in Economics (Institute for Mathematical Economy), Univ. of Freiburg.
1992 – 1995: Germany / Freiburg: General Manager of the Tumor Biology Center in Freiburg i. Brsg. – founded the largest Cancer Research Clinic in Germany – an Institution consisting of a Clinic for Acute Treatment, a Center for Oncological Rehabilitation, Fundamental Research, and Cancer Drug Development.
1995 – 2000: China / Shanghai & Beijing: General Manager of two Joint Ventures in Life Sciences (Animal Health- Shanghai /Novartis and Pharma- Beijing / Aventis), Member of the Asia Executive Committee – Headquarters in Tokyo.
2000 – 2002: France / Strasbourg: Head of Planning, Deputy Head Investor Relations- Aventis.
2002 – 2022: (retirement) Basel: Hoffmann La Roche: Member of the Finance Leadership Team
- Head of Investor Relations, a key member of the Genentech acquisition (largest cash transaction in the financial market so far (>CHF 40bn) / financing in mid of Lehman crisis), the transfer of the Roche shares from Novartis to Roche (largest Swiss capital market transaction),
- Roche with strong market cap development (tripled)
- Head of Corporate Planning (mid/long term Plan)
- Member of the Corporate Sustainability Committee
- Member of the Roche Anlage Commission (Pension Fund- CHF 12 bn)
Since retirement: Senior Adviser for McKinsey – worked on projects in several industries (IT, Transportation, Banking, and Healthcare sectors)- Capital Market Days, Equity story, Investor targeting, onboarding of CFOs and CEOs
- Invited as a conference speaker (Euronext IPO day, etc.)
- Advisor to large European Cap Companies (Capital Market related)
Awards*:
- Best IR Professional ranked by the Buy and Sell side (26 times in 20 years)
- Highlighted in IR magazine as one of the top 30 in the past 30 years
- First IR Professional inaugurated in the Hall of Fame of Global Executives in the Financial Market
